Comparative Pharmacology
Head-to-head clinical analysis: BETADERM versus CAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETADERM versus CAPEX.
BETADERM vs CAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins (lipocortins) and inhibition of arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Topical: Apply a thin film to affected skin twice daily; maximum 100 g per week for adults.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life is approximately 18-36 hours (mean ~24 hours) following topical application; systemic half-life after oral administration is similar, reflecting prolonged tissue retention.
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Renal excretion of metabolites (mainly as glucuronide and sulfate conjugates) accounts for approximately 60-70% of elimination; fecal/biliary excretion accounts for 30-40%.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid